CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still ...

European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the ...

In a recent landmark study, scientists have unveiled how HIV-1 penetrates the cell's nuclear barrier—a discovery that could reshape antiviral strategies. The research, led by Professor Peijun Zhang, ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new ...

MIT's new dual-adjuvant vaccine offers strong HIV protection with a single dose, potentially aiding in the fight against challenging viruses.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

HIV discovery could open door to long-sought cure Date: May 30, 2025 Source: University of Virginia Health System Summary: New HIV research shows that small changes in the virus affect how quickly ...

The study found that viruses with low Rev activity had a disadvantage in both replication and latency reactivation. This variability helps explain why HIV persists despite aggressive treatment.